Genmab & AbbVie’s Epcoritamab Phase 3 Trial Fails to Improve U.S. OS in Relapsed DLBCL
Genmab and AbbVie reveal that the U.S. phase‑3 EPCORE DLBCL‑1 trial of epcoritamab failed to improve overall survival in relapsed/refractory DLBCL, raising regulatory questions.
4 minutes to read
